Author

H. Mitsuya

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 6 Organism:human· 4 Assay:proteomics· 2 Organism:mouse· 1 Organism:virus· 1

Frequent Co-Authors

K. Maeda· 3 shared K. Omata· 2 shared M. Parniak· 2 shared P. R. Tedbury· 2 shared S. G. Sarafianos· 2 shared S.-i. Hattori· 2 shared T. Suzuki· 2 shared Y. Takamatsu· 2 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

K. Maeda

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

HIV-1 resistance to islatravir/tenofovir combination therapy in wild-type or NRTI resistant strains of diverse HIV-1 subtypes

M. A. Cilento, X. Wen, A. B. Reeve, A. Snyder, O. Ukah, C. M. Carrillo, C. P. Smith, K. Edwards, C. C. Wahoski, D. R. Kitzler, E. N. Kodama, H. Mitsuya, M. Parniak, P. R. Tedbury, S. G. Sarafianos

This study evaluates resistance to islatravir and tenofovir in HIV-1 strains with mutations K65R, M184V, and S68G/N, showing that their combination has a high genetic barrier to resistance.

bioRxiv · Jun 18, 2023 · PreprintMicrobiology

SARS-CoV-2-neutralizing humoral IgA response occurs earlier but modest and diminishes faster compared to IgG response.

Y. Takamatsu, K. Omata, Y. Shimizu, N. Kinoshita-Iwamoto, M. Terada, T. Suzuki, S. Morioka, Y. Uemura, N. Ohmagari, K. Maeda, H. Mitsuya

This study compares the neutralizing activity of IgA and IgG antibodies against SARS-CoV-2 in COVID-19 patients and vaccine recipients, finding that IgA response is modest, peaks earlier, and declines faster than IgG.

bioRxiv · Jun 9, 2022 · PreprintMicrobiology

A widely-distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro

K. Matsuda, S. Islam, T. Takada, K. Tsuchiya, B. J. Y. Tan, S.-i. Hattori, H. Katsuya, K. Kitagawa, K. S. Kim, M. Matsuo, N. S. Delino, H. Gatanaga, K. Yoshimura, S. Matsushita, H. Mitsuya, , K. Maeda

The paper develops a new assay to evaluate latency-reversing agents by eliminating HIV-1 proviruses in a long-term cell culture system.

Cell Reports Methods · Dec 1, 2021Peer-reviewedMicrobiology

Highly-Neutralizing COVID-19-Convalescent-Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.

Y. Takamatsu, M. Imai, K. Maeda, N. Nakajima, N. Higashi-Kuwata, K. Iwatsuki-Horimoto, M. Ito, M. Kiso, T. Maemura, Y. Takeda, K. Omata, T. Suzuki, Y. Kawaoka, H. Mitsuya

This study shows that highly-neutralizing COVID-19 convalescent plasmas significantly reduce SARS-CoV-2 viral titers and lung lesions in Syrian hamsters compared to moderately neutralizing plasmas.

bioRxiv · Jun 29, 2021Microbiology

Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300

D. A. Davis, H. Bulut, P. Shrestha, A. Yaparla, H. K. Jaeger, S.-i. Hattori, P. Wingfield, H. Mitsuya, R. Yarchoan

This study shows that SARS-CoV-2 main protease (Mpro) activity and dimerization are regulated by reversible glutathionylation of Cys300, offering a new target for antiviral agents.

bioRxiv · Apr 9, 2021Microbiology

Development of Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine (EFdA) by Wild-Type and Nucleoside Reverse Transcriptase Inhibitor Resistant Human Immunodeficiency Virus Type 1

M. E. Cilento, E. Michailidis, T. V. Ilina, E. Nagy, H. Mitsuya, M. Parniak, P. R. Tedbury, S. G. Sarafianos

This study identifies mutations conferring resistance to EFdA in HIV-1, showing M184V as the primary determinant and A114S enhancing resistance.

bioRxiv · Sep 4, 2020Microbiology